Date lodged: 22 October 2018
To ask the Scottish Government which neonatal units and paediatric units offer respiratory syncytial virus (RSV) vaccination to at-risk babies, in line with Joint Committee on Vaccination and Immunisation guidance.
Answered by: Joe FitzPatrick 23 November 2018
Each NHS board has access to a passive immunisation medical product (Palivizumab) that can reduce the worst complications of RSV in those young children at the greatest risk of complications of RSV once they have become infected with this virus. All eligible children will be under the care of hospital based paediatricians, and therefore the use of palivizumab is determined by them on a clinical basis, in the RSV season.